Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 595

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 595
---
Tech II Acquisition Corp. (“FutureTech II”), see Note 8.

| F-75 |

aegeria soft tissue llc

notes to the financial statements (UNAUDITED)

Note 8 – Merger Agreements

Denali Capital Acquisition Corp. Merger Agreement

On January 25, 2023, pursuant to the objectives of the Acquisition Transactions contemplated by the C&E Agreement and the agreements with the other Target Companies, Longevity entered into an Agreement and Plan of Merger (the “Denali Merger Agreement”) with Denali Capital Acquisition Corp. (“Denali”), a blank-check special purpose acquisition company, Denali SPAC Holdco, Inc. (“New Pubco”), Denali SPAC Merger Sub, Inc., Longevity Merger Sub, Inc., and Bradford A. Zakes (Longevity CEO), in the capacity as seller representative.

On June 27, 2024, Denali and Longevity mutually agreed to terminate the Denali Merger Agreement.

FutureTech II Acquisition Corp. Merger Agreement

On September 16, 2024, pursuant to the objectives of the Acquisition Transactions contemplated by the C&E Agreement and the agreements with the Target Companies, Longevity entered into an Agreement and Plan of Merger (the “ FutureTech II Merger Agreement”) with FutureTech II, a blank-check special purpose acquisition company. Pursuant to the FutureTech II Merger Agreement, the parties thereto will enter into a business combination transaction (the “Business Combination” and together with the other transactions contemplated by the FutureTech II Merger Agreement, the “Transactions”), pursuant to which, among other things, (i) Longevity will consummate the Acquisition Transactions upon the terms and subject to conditions set forth therein and pursuant to the C&E Agreements, and (ii) immediately following the consummation of the Acquisition Transactions, Longevity will merge with and into Merger Sub (the “Merger”) with Longevity as the surviving company of the Merger. Following the Merger, Longevity will be a wholly-owned subsidiary of the FutureTech II. At the closing of the Transactions (“Closing”), FutureTech II will change its name to Longevity Biomedical, Inc., and its common stock is expected to list on Nasdaq under the ticker symbol “LBIO.”

The aggregate consideration (the “Merger Consideration”) to be paid to the holders of Longevity common stock, par value $0.0001 per share (the “Longevity Common Stock”), at the Closing